399 related articles for article (PubMed ID: 27187785)
21. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive review of pacritinib in myelofibrosis.
Verstovsek S; Komrokji RS
Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
[TBL] [Abstract][Full Text] [Related]
23. Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
[TBL] [Abstract][Full Text] [Related]
24. Safety evaluation of ruxolitinib for treating myelofibrosis.
Galli S; McLornan D; Harrison C
Expert Opin Drug Saf; 2014 Jul; 13(7):967-76. PubMed ID: 24896661
[TBL] [Abstract][Full Text] [Related]
25. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.
Mascarenhas J; Virtgaym E; Stal M; Blacklock H; Gerds AT; Mesa R; Ganly P; Snyder D; Tabbara I; Tremblay D; Moshier E
Ann Hematol; 2018 Aug; 97(8):1369-1374. PubMed ID: 29616317
[TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
30. The role of pacritinib in the management of myelofibrosis.
Duong VH; Komrokji RS
Expert Rev Hematol; 2014 Jun; 7(3):325-32. PubMed ID: 24746271
[TBL] [Abstract][Full Text] [Related]
31. Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A; Tefferi A
Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025
[TBL] [Abstract][Full Text] [Related]
32. Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Heine A; Wolf AM; Schlaweck S; Daecke SN; Brossart P; Wolf D
Exp Hematol; 2021 Aug; 100():37-40. PubMed ID: 34182006
[TBL] [Abstract][Full Text] [Related]
33. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
34. The new landscape of therapy for myelofibrosis.
Gowin K; Emanuel R; Geyer H; Mesa RA
Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
[TBL] [Abstract][Full Text] [Related]
35. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy of Myelofibrosis.
Tremblay D; Marcellino B; Mascarenhas J
Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
[TBL] [Abstract][Full Text] [Related]
37. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
38. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
40. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
